Opioid Antagonists
Key Points
- Opioid antagonists competitively block opioid receptors and reverse opioid-induced CNS/respiratory depression.
- Naloxone is the emergency antidote for suspected opioid overdose and can be given IV, IM, or intranasally.
- Naloxone duration is short (commonly about 20-30 minutes), so re-sedation can occur and urgent medical follow-up is mandatory.
- Naltrexone is used for relapse prevention/abstinence support, not for immediate overdose reversal, and is generally started only after an opioid-free interval.
- Nalbuphine is a mixed agonist-antagonist that can provide analgesia and can antagonize some opioid-depressant effects at lower doses.
- In chronic opioid users, antagonists can precipitate acute withdrawal with agitation, diarrhea, and severe dysphoria.
Drug Class Overview
Opioid antagonists are used to counter opioid agonist effects when toxicity occurs or to reduce relapse reinforcement during recovery care. Their clinical role differs by agent: some are emergency rescue drugs and others are maintenance medications.
Major Agents
| Agent | Primary Role | Typical Adult Dosing Context | Key RN Safety Points |
|---|---|---|---|
| Naloxone hydrochloride (Narcan) | Emergency reversal of known/suspected opioid overdose | IV 0.4-2 mg as needed; intranasal 4-8 mg every 2-3 minutes until medical help is available | Monitor breathing continuously; repeat dosing may be required due to short duration |
| Naltrexone hydrochloride (Vivitrol) | Opioid-abstinence support and relapse prevention | Oral 25-50 mg daily; IM 380 mg every 4 weeks | Ensure opioid-free period before initiation to reduce precipitated-withdrawal risk |
| Nalbuphine hydrochloride (Nubain) | Mixed agonist-antagonist analgesic pathway | 10 mg SC/IM/IV every 3-6 hours as needed | Can serve as analgesic alternative; monitor for withdrawal symptoms if opioid dependent |
Nursing Assessment
- In suspected overdose, prioritize airway, respiratory pattern, oxygenation, and level of consciousness.
- Assess for co-ingestion of other CNS depressants (for example benzodiazepines, alcohol, sedative-hypnotics) because mixed intoxication can persist after opioid reversal.
- Assess opioid-use history; chronic opioid exposure increases risk for precipitated withdrawal after antagonist dosing.
- For naltrexone initiation planning, verify abstinence context and readiness for sustained adherence.
- Verify opioid-free period before naltrexone start (commonly about 5-7 days) to lower precipitated-withdrawal risk.
Nursing Interventions
- Administer naloxone rapidly for suspected opioid overdose and repeat per response while activating emergency services.
- Reassess respiratory status frequently after initial response because opioid effects can outlast naloxone.
- Use titrated naloxone dosing when possible in opioid-dependent clients to restore ventilation while limiting abrupt severe withdrawal.
- For naltrexone therapy, reinforce scheduled dosing and follow-up monitoring for adherence and relapse risk.
- For nalbuphine use, monitor analgesic response, sedation, blood pressure, and signs of withdrawal in dependent clients.
Re-Sedation Risk
Improvement after naloxone does not equal clinical stability. Because many opioids last longer than naloxone, recurrent respiratory depression can occur within minutes.
Patient Education
- Keep naloxone accessible in high-risk households and teach bystander administration steps.
- Educate families that naloxone nasal spray is available over the counter in the United States, which supports faster community access.
- Seek emergency medical care after any naloxone use, even if the person wakes up.
- Do not use opioids while taking naltrexone; receptor blockade can precipitate withdrawal and disrupt treatment planning.
- Report severe agitation, persistent vomiting/diarrhea, or recurrent drowsiness immediately after antagonist use.
Related Concepts
- opioids - Opioid agonist pharmacology and overdose-risk monitoring.
- opioid-use-disorder - Overdose response and medication-assisted treatment pathways.
- dealing-with-addiction - Recovery-continuum planning and relapse-prevention support.
- pain-management - Multimodal analgesia and opioid safety workflows.
Self-Check
- Why must all clients who receive naloxone still be monitored in an emergency setting?
- How does naltrexone’s role differ from naloxone in opioid-related care?
- What withdrawal-pattern cues can appear after antagonist use in opioid-dependent clients?